A Year Into Its Biggest Biotech Bet, Armistice Capital’s Book Still Has Room for Penny Stocks
Seven hundred cardiologists sat through REMS registration and training within weeks of a single drug’s launch in January. Cytokinetics had more than 125 field sales...